Our results showed that atorvastatin and ezetimibe could prevent HCD-induced lung fibrosis by downregulating the TGF-β-SMAD2/3 signaling pathway and enhancing MMP-19 expression, but not by modulating pro-fibrotic enzyme action. This evidence concerns the gene MMP19 and heavy chain disease.